We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current VYGR market cap is 307M. The company's latest EPS is USD 2.4225 and P/E is 2.34.
Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 150.48M | 4.85M | 4.61M | 90.06M | 19.52M |
Operating Income | 122.88M | -25.43M | -29.51M | 54.06M | -16.18M |
Net Income | 124.04M | -22.21M | -25.9M | 56.4M | -11.33M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 104.39M | 171.13M | 37.42M | 40.91M | 250.01M |
Operating Income | -51.68M | 27.38M | -73.62M | -50.84M | 122.01M |
Net Income | -43.6M | 36.74M | -71.2M | -46.41M | 132.33M |
Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 336.29M | 315.54M | 294.65M | 351.28M | 469.59M |
Total Liabilities | 119.33M | 116.51M | 118.43M | 114.96M | 128.71M |
Total Equity | 216.96M | 199.03M | 176.22M | 236.32M | 340.89M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 354.76M | 261.58M | 193.86M | 159.36M | 351.28M |
Total Liabilities | 255.25M | 107.26M | 98.8M | 100.34M | 114.96M |
Total Equity | 99.51M | 154.32M | 95.06M | 59.02M | 236.32M |
Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 123.57M | 122.73M | 101.68M | 77.92M | 58.77M |
Investing | 14.49M | -10.17M | -168.48M | -141.64M | -96.07M |
Financing | 31.31M | 32.85M | 33.19M | 33.65M | 112.86M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 48.67M | -96.72M | -53.53M | -12.51M | 77.92M |
Investing | -90.48M | 113M | 65.91M | -7.34M | -141.64M |
Financing | 80.99M | 3.16M | 612k | 1.11M | 33.65M |
Market Cap | 307M |
Price to Earnings Ratio | 2.34 |
Price to Sales Ratio | 1.24 |
Price to Cash Ratio | 4.49 |
Price to Book Ratio | 1.31 |
Dividend Yield | - |
Shares Outstanding | 54.63M |
Average Volume (1 week) | 460.47k |
Average Volume (1 Month) | 568.79k |
52 Week Change | -17.72% |
52 Week High | 11.72 |
52 Week Low | 5.19 |
Spread (Intraday) | 0.45 (7.51%) |
Company Name | Voyager Therapeutics Inc |
Address |
corporation trust center wilmington, delaware 19801 |
Website | https://www.voyagertherapeutics.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions